Mutational analysis of p53 in 16 cases of acute lymphoblastic leukemia and Burkitt's lymphoma

Haematologica

Volumn 82, Issue 5, 1997, Pages 550-554

  Nomdedéu, Josep F ^a   Lete, Ignacio ^a   Baiget, Montserrat ^a   Lasa, Adriana ^a   Estivill, Camino ^a   Rubiol, Enriqueta ^a   Badell, Isabel ^a   Pardo, Nuria ^a   Cubells, Josep ^a   Mateu, Roser ^a   Brunet, Salut ^a   Bordes, Ramón ^a   Soler, Jesús ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acute lymphoblastic leukemia; Burkitt lymphoma; Molecular genetics; Mutation; p53

Indexed keywords

DNA; PROTEIN P53;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, B-CELL, ACUTE; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031466913     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995; 80:280-91.
2. Bassan R, Lerede T, Barbui T. Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. Haematologica 1996; 81:20-36.
3. Lerede T, Bassan R, Rossi A, et al. Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. Haematologica 1996; 81: 442-9.
4. Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 1995, 13; 812-820.
5. Imamura J, Miyoshi I, Koeffler P. p53 in hematologic malignancies. Blood 1994, 84:2412-21.
6. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991, 88:5413-7.
7. Bhatia K, Gutiérrez MI, Huppi K, Siwarski D, Magrath IT. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 1992, 52; 4273-6.
8. Dicciani MB, Yu J, Hsiao S, Mukherjee S, Shao LE, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994, 84:3105-12.
9. Lo Coco F, Gaidano G, Luie DC, Offit K, Chaganti RSK, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993, 82:2289-95.
10. Hernández L, Fest T, Cazorla M, et al. p53 mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996, 87:3351-9.
11. Ichikawa A, Hotta T, Takagi N, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992, 79:2701-7.
12. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996, 87:4302-10.
13. Felix C, Wasserman R, Lange BJ, et al. Differentiation stages of childhood acute lymphoblastic leukemias with p53 mutations. Leukemia 1994, 8:963-7.
14. Marks DI, Kurz BW, Link MP, et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996, 87:1155-61.
15. Lanza C, Gaidano G, Cimino G, et al. p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints ac 11q23 and 8q24. Leukemia 1995; 9:955-959.
16. Kawamura M, Kikuchi A, Kobayashi S, et al. Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia. Blood 1995, 85:2546-52.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976, 33:451-8.
18. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84;1361-1392.
19. Miller SA, Dykesd DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16:1215.
20. Korsmeyer SJ, Hyeter PA, Ravtech JV, Poplack DG, Waldmann TA, Leder P. Developmental hierarchy of immunoglobulin gene rearrangement in human leukemic pre-B cells. Proc Natl Acad Sci USA 1981; 78:7096-100.
21. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79:7824-7.
22. Petroni D, Lasa A, Pastore C, Baiget M, Soler J, Nomdedéu J. Rapid sequencing protocol using microconcentrators. Trends Genet 1996; 12:167-8.
23. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70:523-6.
24. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996; 12:1379-85.
25. Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J Clin Invest 1992; 90:1637-41.
26. De Vries EMG, Ricke DO, De Vries TN, et al. Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. Hum Mutat 1996, 7:202-13.
27. Wu JK, Ye Z, Darras BT. Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cells populations. Am J Hum Genet 1993; 52:1273-5.
28. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nature Genet 1993, 4:42-5.
29. Bhatia K, Goldschmidts W, Gutiérrez M, Gaidano G, Dalla Favera R, Magrath I. Hemi- or homozygosity: a requirement for some but not other p53 mutant protein to accumulate and exert a pathogenic effect. FASEB J 1993; 7:951-6.
30. Newcomb E. p53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 1995; 17:211-21.
31. Harris CC. The 1995 Walter Hubert lecture- molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumor-suppressor gene. Br J Cancer 1996, 73:261-9.
32. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995, 11; 763-70.
33. Varley JM, McGown G, Thorncroft M, et al. A previously undescribed mutation within the tetramerization domain of Tp53 in a family with Li-Fraumeni syndrome. Oncogene 1996; 12:2437-42.
34. Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, Fujinaga K. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53 transactivation activity. Oncogene 1996; 12:2361-7.
35. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
36. Gaidano G, Pastore C, Volpe G. Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Haematologica 1995; 80:454-72.